Story

Morgan Stanley Upgrades Roche to Overweight on Drug Pipeline Momentum

ENTHMSVIIDZHZH-TWJAKOHI
Aug 7, 20262 min read
Morgan Stanley Upgrades Roche to Overweight on Drug Pipeline Momentum
Text size
Background

Morgan Stanley has upgraded Swiss pharmaceutical giant Roche Holding AG to "Overweight" from "Equal-weight", citing a strengthening drug pipeline and the significant commercial potential of its breast cancer treatment, giredestrant. The bank also raised its price target for Roche's Swiss-listed shares to SFr 410 from SFr 295, implying roughly 12% upside from the previous day's close.

The Upgrade Details

In a note to clients, Morgan Stanley analysts detailed the basis for their more bullish stance, adding Roche as a new "Top Pick" in the European pharma sector, replacing AstraZeneca. The price target for Roche's U.S.-listed American Depositary Receipts (ADR) was also increased to $63 from $46.

The bank's revised forecasts are notably ahead of market consensus. Morgan Stanley's 2027 core earnings per share (EPS) estimate for Roche is SFr 22.96, which stands 5.2% above the current consensus of SFr 21.83. Their estimates for 2028 and 2029 are also 3.6% and 4.5% ahead of the Street, respectively.

Giredestrant in Focus

The primary driver for the upgrade is the anticipated successful launch of giredestrant, a breast cancer drug. Morgan Stanley pointed to two key U.S. Food and Drug Administration (FDA) approval decisions expected in late 2026.

Sample IUX Markets – In-articleAd

The bank projects a larger and faster-than-expected launch, with key forecasts including:

  • First-year sales of approximately CHF 660 million (about $800 million).
  • Total peak sales for giredestrant reaching CHF 9 billion (about $11 billion).
  • This peak sales forecast is substantially higher than the market consensus of approximately CHF 6.6 billion.

Broader Pipeline and Valuation

Beyond giredestrant, Morgan Stanley highlighted other promising assets in Roche's pipeline that could drive growth from 2027 onward. These include afimkibart for ulcerative colitis (guided for >CHF 3 billion in peak sales), Columvi for blood cancer (a ~CHF 1.6 billion opportunity), and trontinemab for Alzheimer's disease (potential for >$5 billion in peak sales).

From a valuation perspective, the analysts acknowledged that Roche trades at a premium to its European large-cap pharma peers, at approximately 15.5 times its estimated 2027 price-to-earnings (P/E) ratio. However, they argued this premium is justified by improving earnings visibility and a lower-risk growth profile compared to competitors like AstraZeneca and Novartis. The bank's bull case scenario places the stock at SFr 460, while the bear case is SFr 300.

Read next

More on Stocks
Back to latest news

LATEST